- Home
- BOF vs SABS Comparison
BOF vs SABS Comparison
Compare BOF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOF
- SABS
- Stock Information
- Founded
- BOF 2017
- SABS 2014
- Country
- BOF United States
- SABS United States
- Employees
- BOF N/A
- SABS N/A
- Industry
- BOF Packaged Foods
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BOF Consumer Staples
- SABS Health Care
- Exchange
- BOF Nasdaq
- SABS Nasdaq
- Market Cap
- BOF 18.3M
- SABS 15.8M
- IPO Year
- BOF 2023
- SABS N/A
- Fundamental
- Price
- BOF $2.29
- SABS $1.85
- Analyst Decision
- BOF
- SABS Strong Buy
- Analyst Count
- BOF 0
- SABS 6
- Target Price
- BOF N/A
- SABS $11.17
- AVG Volume (30 Days)
- BOF 62.2K
- SABS 42.7K
- Earning Date
- BOF 05-27-2025
- SABS 05-27-2025
- Dividend Yield
- BOF N/A
- SABS N/A
- EPS Growth
- BOF N/A
- SABS N/A
- EPS
- BOF N/A
- SABS N/A
- Revenue
- BOF $6,516,337.00
- SABS $377,835.00
- Revenue This Year
- BOF N/A
- SABS N/A
- Revenue Next Year
- BOF N/A
- SABS $50.00
- P/E Ratio
- BOF N/A
- SABS N/A
- Revenue Growth
- BOF 130.60
- SABS N/A
- 52 Week Low
- BOF $0.61
- SABS $1.00
- 52 Week High
- BOF $4.11
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- BOF 65.79
- SABS 60.23
- Support Level
- BOF $1.92
- SABS $1.67
- Resistance Level
- BOF $2.38
- SABS $2.15
- Average True Range (ATR)
- BOF 0.11
- SABS 0.18
- MACD
- BOF 0.04
- SABS 0.03
- Stochastic Oscillator
- BOF 82.82
- SABS 57.75
About BOF BranchOut Food Inc.
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.